Jefferies London 2026: The phase 3 OPERA-01study of Olema's CERAN + SERD, palazestrant, is setting up to be one of biotech's key readouts and is quickly approaching and scheduled to read in 1Q27

From BiotechTV - News · 00:11:42

Show by BiotechTV

CEO Sean Bohen reminds us of the mechanism and the design of this monotherapy study, which is in the 2/3 line ER+/HER2 metastatic breast cancer setting. He also discusses why he believes the OPERA-02 study in 2nd line in combo with a CDK 4/6 can succeed where a competitor failed earlier this year.

More episodes of BiotechTV - News

More episodes

PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.